Women with T2D Less Likely to Receive Guideline-recommended Cardiovascular Care vs Men
EASD 2021: Women with type 2 diabetes were less likely to meet targets for CV risk management vs men but at lower risk for future CV events, a new study found.
COVID-19 Updates: Delta Variant, US Vaccinations, & Global Data as of September 27, 2021
Data from the CDC on the Delta variant and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
H Pylori Independently Associated with Carotid Plaque Formation, Investigators Find
Helicobacter pylori infection in early-middle-aged adults was associated with higher BMI, triglyceride levels, carotid plaque formation, and carotid intima-media thickness.
COVID-19 Boosters: Hope or Hype?
Infectious disease expert and NIH-funded researcher Rodger MacArthur, MD, has questions about the evidence on which the Pfizer booster shot recommendations are based.
Study: Safety Data on HPV Vaccine Improving, but More Parents Still Concerned
A new analysis showed a near 78% increase in citing safety concerns among parents with HPV vaccine hesitancy, contrary to no observed changes in serious adverse event reporting.
COVID-19 Updates: Delta Variant, US Vaccinations, & Global Data as of September 24, 2021
Drug & Alcohol Use Among Young Adults: 2020 Monitoring the Future Survey Results
The annual NIH-supported survey revealed changing substance use trends among college students and college-aged adults. Find key results for primary care in our quick slideshow.
Early LDL-C Exposure and Cumulative Burden Increase CHD Risk in Middle Age
Clinical decisions on LDL-C management currently rely on a measure at one time point, typically middle age. A new study suggests burden begins early and so should assessment.
COVID-19 Updates: Delta Variant, US Vaccinations, & Global Data as of September 23, 2021
The State of American Obesity 2021
More than half of adults in every US state had either overweight or obesity in 2020. This at-a-glance slide show reports more findings from an annual compilation of public data.
Remdesivir May Significantly Reduce Risk of Hospitalization in High-risk COVID-19 Patients, Suggests New Study
Findings from a phase 3 clinical trial showed remdesivir reduced the risk of COVID-19-related hospitalizations by 87% in high-risk patients, the drug's manufacturer announced.
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine Booster for Select Groups
The Pfizer-BioNTech booster shot is authorized for use in persons aged ≥65 years, at high risk of severe disease, and who have frequent exposure to the virus increasing risk for severe infection.
COVID-19 Updates: Delta Variant, US Vaccinations, & Global Data as of September 22, 2021
AHA: Metabolic Surgery, Medication Effective for Management of Obesity-related Hypertension
A new AHA scientific statement suggests metabolic surgery and weight-loss medications may reduce the long-term effects of obesity-related hypertension.
8 Hypertension Research Recaps for Primary Care
New hypertension research looks at stress hormones in early disease, the Quadpill as first Rx, tight BP control for older adults--for a start. We recap 8 new studies.
COVID-19 Updates: Delta Variant, US Vaccinations, & Global Data as of September 21, 2021
Work Environment May Trigger Asthma in Some Employees, New Research Suggests
A variety of exposures in the work environment can cause asthma in some employees, according to new research presented at ERS Virtual International Congress 2021.
J&J Preprint Data Show Real-world Durability, Promise for Booster Shot Against COVID-19
Strong evidence from a large, real-world evidence study, and preliminary data from a phase 3 booster-dose trial may support J&J's next steps toward FDA authorization of a COVID-19 booster.
COVID-19 Updates: Delta Variant, US Vaccinations, & Global Data as of September 20, 2021
CDC: Moderna Vaccine Shows Highest Efficacy Against Hospitalizations in Healthy Adults
In a new analysis of adults without immunocompromising conditions, vaccine effectiveness against hospitalization was higher for Moderna than Pfizer and Johnson & Johnson.